EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States

Markella V Zanni, Borek Foldyna iD, Sara McCallum, Tricia H Burdo, Sara E Looby, Kathleen V Fitch, Evelynne S Fulda, Patrick Autissier, Gerald S Bloomfield, Carlos D Malvestutto, Carl J Fichtenbaum, Edgar T Overton und 12 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Markella V Zanni und 23 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Plaque, Atherosclerotic, Coronary Artery Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIA NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Among people with HIV (PWH), sex differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, or relationships therein.

Methods

REPRIEVE, a primary ASCVD prevention trial, enrolled antiretroviral therapy (ART)–treated PWH. At entry, a subset of US participants underwent coronary computed tomography angiography (CTA) and immune phenotyping (n = 755 CTA; n = 725 CTA + immune). We characterized sex differences in coronary plaque and immune/inflammatory biomarkers and compared immune-plaque relationships by sex. Unless noted otherwise, analyses adjust for ASCVD risk score.

Results

The primary analysis cohort included 631 males and 124 females. ASCVD risk was higher among males (median: 4.9% vs 2.1%), while obesity rates were higher among females (48% vs 21%). Prevalence of any plaque and of plaque with either ≥1 visible noncalcified portion or vulnerable features (NC/V-P) was lower among females overall and controlling for relevant risk factors (RR [95% CI] for any plaque: .67 [.50, .92]; RR for NC/V-P: .71 [.51, 1.00] [adjusted for ASCVD risk score and body mass index]). Females showed higher levels of IL-6, hs-CRP, and D-dimer and lower levels of Lp-PLA2 (P < .001 for all). Higher levels of Lp-PLA2, MCP-1, and oxLDL were associated with higher plaque (P < .02) and NC/V-P prevalence, with no differences by sex. Among females but not males, D-dimer was associated with higher prevalence of NC/V-P (interaction P = .055).

Conclusions

Among US PWH, females had a lower prevalence of plaque and NC/V-P, as well as differences in key immune/inflammatory biomarkers. Immune-plaque relationships differed by sex for D-dimer but not other tested parameters. Clinical Trial Registration. ClinicalTrials.gov; identifier: NCT0234429 (date of initial registration: 22 January 2015).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisPlaque, AtheroscleroticCoronary Artery DiseaseHumansFemaleMaleUnited StatesHIVSex Characteristics1-Alkyl-2-acetylglycerophosphocholine EsteraseRisk FactorsInflammationBiomarkers

Stichwörter der Autor:innen

HIVcoronary atherosclerosisinflammationreproductive agingwomen

Substanzen

1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkers

Autor:innen und Institutionen

  • Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Microbiology, Immunology, and Inflammation and Center for NeuroVirology and Gene Editing, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
  • Yvonne L. Munn Center for Nursing Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Biology , Boston College, Chestnut Hill, Massachusetts, USA.
  • Department of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Borek Foldyna

Förderung

  • NIAID NIH HHS
  • NIA NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health (NIH), National Institute of Heart, Lung, and Blood Institute
  • REPRIEVE Clinical Coordinating Center
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Zanni, M. V., Foldyna, B., McCallum, S., Burdo, T. H., Looby, S. E., Fitch, K. V., Fulda, E. S., Autissier, P., Bloomfield, G. S., Malvestutto, C. D., Fichtenbaum, C. J., Overton, E. T., Aberg, J. A., Erlandson, K. M., Campbell, T. B., Ellsworth, G. B., Sheth, A. N., Taiwo, B., Currier, J. S., …, & Grinspoon, S. K. (2023). Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac767

Vancouver

Zanni MV, Foldyna B, McCallum S, Burdo TH, Looby SE, Fitch KV, et al. Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac767

BibTeX
@article{Zanni2023,
  author = {Zanni, Markella V and Foldyna, Borek and McCallum, Sara and Burdo, Tricia H and Looby, Sara E and Fitch, Kathleen V and Fulda, Evelynne S and Autissier, Patrick and Bloomfield, Gerald S and Malvestutto, Carlos D and Fichtenbaum, Carl J and Overton, Edgar T and Aberg, Judith A and Erlandson, Kristine M and Campbell, Thomas B and Ellsworth, Grant B and Sheth, Anandi N and Taiwo, Babafemi and Currier, Judith S and Hoffmann, Udo and Lu, Michael T and Douglas, Pamela S and Ribaudo, Heather J and Grinspoon, Steven K},
  title = {Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac767}
}
Kostenlos starten →